DaVita Clinical Research
825 South 8th Street
Minneapolis, Minnesota 55404
888-345-2567 http://www.dcrmn.com Halcorn@dcrmn.com

Use our guide to learn which trials are right for you!

DaVita Clinical Research (DCR) is a full-service Phase I-IV renal clinical trial site and Site Management Organization. A subsidiary of DaVita, Inc., one of the largest providers of dialysis services in the United States, DCR has over 15 years of experience as a recognized leader in renal clinical trials for pharmaceutical drugs and devices. DCR is a private trial site located in Minneapolis, MN, with access to many local and national patient populations. Nationally, DCR has access to over 400 dialysis facilities and over 38,000 end-stage renal disease patients.

DaVita Clinical Research is committed to the success of customer's studies, by providing uncompromising quality and timely, cost-effective professional services. DCR is unique, providing Phase I-IV renal clinical trials/510(k) approval capabilities, quick local IRB approval, rapid enrollment of patients, and Board Certified physicians committed to quality management of all protocol research activities in areas such as:

  • End-Stage Renal Disease (ESRD)
  • Renal Insufficiency

Since 1983, DCR has conducted clinical trials for the following sponsors:

  • Abbott Labs
  • Abgenix, Inc.
  • Alpha-Beta Technology
  • Alquest, Inc.
  • Alteon Inc.
  • American Cyanamid Company
  • Amgen Inc.
  • Amylin Pharmaceuticals, Inc.
  • AstraZeneca Pharmaceuticals
  • Aventis
  • Baxter Healthcare Corporation
  • Bayer
  • Berlex Laboratories, Inc.
  • Biogen
  • Bracco Diagnostics, Inc.
  • Bristol-Myers Squibb
  • Cato Research
  • Cellegy Pharmaceuticals
  • Centocor, Inc.
  • Chugai-Upjohn, Inc.
  • Colgate
  • Corgentech, Inc.
  • Covance Inc.
  • Cubist Pharmaceuticals
  • Diatide Research Laboratories
  • Discovery Therapeutics
  • Du Pont Merck
  • Eisai America, Inc.
  • Elan
  • Eli Lilly & Company
  • Empherse
  • Ethicon, Inc.
  • Fujisawa
  • Genzyme Corporation
  • GH Besselaar Associates
  • GlaxoSmithKline
  • Hoffmann-LaRoche
  • Idenix Pharmaceuticals
  • Ingenix, Inc.
  • Intercardia, Inc.
  • Janus
  • Liposome Company


  • Mallinkrodt Medical Inc.
  • Maret
  • Medi-Ject Corporation
  • Merck
  • MGI Pharma, Inc.
  • Miles, Inc.
  • Myogen
  • Nabi Biopharmaceuticals
  • National Institute of Health
  • National Kidney Foundation of the Upper Midwest
  • Neurex Inc.
  • Neurocrine Biosciences
  • NeuroMed Technologies, Inc.
  • Novartis
  • Omnicare, Inc.
  • Orphan Medical
  • Ortho Biotech
  • Parke-Davis
  • Pfizer Inc.
  • Pharmacia
  • Pharmaquest for R&D Laboratories, Inc.
  • PharmaNet
  • PPD, Inc.
  • PRA International
  • Proctor & Gamble Co.
  • RPR, Inc.
  • Roche Laboratories
  • Sandoz Research Institute
  • Schein Pharmaceutical Company
  • Schering-Plough Research Institute
  • Scios, Inc.
  • Smith Kline Beecham Pharmaceuticals
  • Syntex Research
  • Takeda America Inc.
  • TAP Pharmaceuticals
  • Texas Biotechnology Corporation
  • University of Minnesota
  • UTI Med
  • Versicor
  • Wyeth-Ayerst
  • Yamanouchi Pharmaceutical Co., Ltd.


Suzanne K. Swan, M.D.
Medical Director of the Clinical Research Unit of DCR; Associate Professor, School of Medicine, University of Minnesota; Board Certified in Internal Medicine, Nephrology, and Clinical Pharmacology; Staff Nephrologist, Division of Nephrology, Hennepin County Medical Center. Research interests are clinical pharmacology of drugs in renal failure, aminoglycoside nephrotoxicity, mechanisms of protection from nephrotoxins, and diuretic pharmacokinetics/pharmacodynamics.

Harry Alcorn, Jr., Pharm.D.
Chief Scientific Officer, DaVita Clinical Research; Adjunct Clinical Professor, College of Pharmacy, University of Minnesota. His responsibilities include management for local and National operations for clinical research for DCR and DaVita, Inc.


Cardiology/Vascular Diseases
Dermatology/Plastic Surgery
Endocrinology
Gastroenterology
Immunology/Infectious Diseases
Musculoskeletal
Nephrology/Urology

Our center features:

  • 55 beds for patient confinement
  • Recreational amenities
  • 24-hour medical coverage
  • Private client monitor rooms
  • Four exam rooms and two large treatment rooms
  • Outpatient blood draw area
  • Sample processing laboratory
  • Freezers (-70 degree Celsius and -20 degree Celsius)
  • Refrigerated centrifuges
  • Computerized EKG machines
  • Laminar flow hood for IV preparation
  • Telemetry capabilities
  • Access to hemodialysis units
  • Registered dietitian consultant
  • Specialty meals
  • Affiliation with two CLIA certified clinical laboratories

DCR's headquarters and phase I unit are located in Downtown Minneapolis, MN, adjacent to Hennepin County Medical Center. We are a ten-minute drive from Minneapolis/St. Paul International Airport.


Harry Alcorn Jr. PharmD., Chief Scientific Officer;
DaVita Clinical Research
825 South 8th Street, Suite 300
Minneapolis, MN 55404
USA
888-345-2567
866-852-3241 (fax)
Halcorn@dcrmn.com
www.dcrmn.com


We've found
15 trials
at this facility
End Stage Renal Disease (ESRD) Clinical Trial
Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
Status: Enrolling, Phase IV
Updated: 11/17/2015
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hepatic Impairment Clinical Trial
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Status: Enrolling, Phase I
Updated: 11/9/2015
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Gastroenterology Clinical Trial
Effect of Hepatic Impairment on LDK378 Pharmacokinetics
Status: Enrolling, Phase I
Updated: 3/3/2016
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Gout Clinical Trial
Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
Status: Enrolling, Phase I
Updated: 1/6/2016
mi
from
Minneapolis, MN
Click here to add this to my saved trials
End Stage Renal Disease Clinical Trial
A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration
Status: Enrolling
Updated: 7/9/2015
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hepatic Impairment Clinical Trial
Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.
Status: Enrolling, Phase I
Updated: 12/22/2015
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
Status: Enrolling, Phase I
Updated: 12/14/2015
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Chronic Kidney Disease Clinical Trial
A Study of LY3113593 in Participants With Chronic Kidney Disease
Status: Enrolling, Phase I
Updated: 4/4/2016
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Nephrology / Urology, Other Clinical Trial
Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer
Status: Enrolling, Phase I
Updated: 1/4/2016
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hepatic Impairment Clinical Trial
A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function
Status: Enrolling, Phase I
Updated: 3/20/2016
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hepatic Impairment Clinical Trial
Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
Status: Enrolling, Phase I
Updated: 3/29/2016
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Smoking Clinical Trial
Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine Gum
Status: Enrolling
Updated: 1/19/2016
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Anemia Clinical Trial
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Status: Enrolling, Phase II
Updated: 3/22/2016
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Nephrology / Urology Clinical Trial
Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting
Status: Enrolling, Phase I, II
Updated: 3/31/2016
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Diabetes Mellitus, Type II Clinical Trial
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
Status: Enrolling, Phase II
Updated: 3/18/2015
mi
from
Minneapolis, MN
Click here to add this to my saved trials